Treatment and prevention of dengue virus infections

Abstract

Methods and pharmaceutical compositions for treating viral infections, by administering certain 2-aryl-benzothiazole or 2-heteroaryl-benzothiazole derivative compounds in therapeutically effective amounts are disclosed. Methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment and prophylaxis of viral infections such as caused by flavivirus is disclosed, i.e., including but not limited to, Dengue virus, West Nile virus, yellow fever virus, Japanese encephalitis virus, and tick-borne encephalitis virus.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to and benefits of US Provisional Application No. 61 / 221,773, filed June 30, 2009, the contents of which are hereby incorporated by reference in their entirety. field of invention [0003] The present invention relates to 2-aryl-benzothiazole or 2-heteroaryl-benzothiazole derivatives and analogs and compositions comprising them for the treatment or prevention of viral diseases associated with the family Flaviviridae (e.g. dengue fever, Fever, West Nile Fever, St. Louis Encephalitis, Hepatitis C, Murray Valley Encephalitis, and Japanese Encephalitis). Background of the invention [0004] Dengue fever (DF) is an acute febrile illness caused by one of four closely related viral serotypes (DEN-1, DEN-2, DEN-3 and DEN-4). Dengue fever is classified according to its clinical features: classic dengue fever, or the more severe forms dengue hemorrhagic fever syndrome (DHF) and dengue shock synd...

AI Technical Summary

Problems solved by technology

While a successful vaccine can be a critical part of effective biodefense, the often delayed timing of onset of immunity, possible side effects, cost, and logistics associated with mass civilian vaccination against low-threat risks imply comprehensive biodefense Include a separate quick response element

Images